AMSA: a phase II trial in resistant and recurrent acute myelogenous leukemia.
27 patients with resistant acute myelogenous leukemia (AML) were treated with AMSA. Three achieved a complete remission, and two a partial remission. Median survival for all patients was 12 weeks and was 16 weeks for responders.
D000609:Aminoacridines / Q000009:adverse effects / Q000627:therapeutic use*; D000677:Amsacrine; D004341:Drug Evaluation; D004351:Drug Resistance; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality; D012008:Recurrence; D013997:Time Factors
D000609:Aminoacridines; D000677:Amsacrine